In the first four months of 2025, Russians’ spending on thyroid medications increased by 20.4% y-o-y. During this period, the Russian market for drugs treating thyroid diseases saw steady growth, with consumers spending approximately 1.1 billion rubles. In terms of units sold, sales reached 7.3 million packages, marking a 9.8% y-o-y rise. Analytical company RNC Pharma noted that this upward trend indicates a gradual recovery of the market following a recession in 2023. The recession was attributed to demand saturation in 2022. The highest sales for this drug category occurred in March 2022, when over 6.9 million packages were sold within a single month.
In retail, thyroid medications are available in a relatively limited range of about 50 stock-keeping units (SKUs). In the first four months of 2025, more than 71% of sales were attributed to thyroid hormones based on levothyroxine sodium. Iodine preparations accounted for nearly 23% of the total market volume, while antithyroid drugs held a share of only 5.8%.
L-Thyroxine remains the leading product in this segment. Three manufacturers produce it, with German Berlin-Chemie, part of the Menarini Group, controlling 96% of sales. The remaining 4% is divided between Russian firms Ozon Pharmatsevtika and PFK Renewal. In terms of market value, L-Thyroxine accounts for 33.8% of the segment.
Merck’s Eutirox is in second place with a 28.3% market share, while Iodomarin from Berlin-Chemie ranks third with 23.7%.
Analysts highlighted some drugs that experienced explosive growth. For example, Propicil, containing propylthiouracil and produced by German firm Admeda Arzneimittel, saw sales increase 293 times in monetary terms and 101 times in units sold. Liquatirol, a new product introduced in retail in late 2024 by Nizhpharm, also showed growth. Conversely, four of the top ten brands experienced declines in sales. The largest decrease, about 50%, was recorded for Microiodide, produced by Tathimpharm.
Earlier, analysts released data on the top 10 nasal rinses, with Aqualor from Russian company Nizhpharm evaluated as the most popular among consumers.
